A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131)
Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes
Mellitus.